Source comparison
Thymosin Alpha-1: Full Comparison
Primary Target T-cell differentiation & dendritic cell maturation via TLR4 signaling Actin polymerization, tissue repair, angiogenesis Direct antiviral via JAK-STAT pathway, broad antiviral gene expression Tα1 is immune modulation; Tβ4 is structural repair; IF
This comparison does not assign a generated winner or score.
- Primary Target
- T-cell differentiation & dendritic cell maturation via TLR4 signaling
- Actin polymerization, tissue repair, angiogenesis
- Direct antiviral via JAK-STAT pathway, broad antiviral gene expression
- Tα1 is immune modulation; Tβ4 is structural repair; IFN-α is direct antiviral. Mechanistically distinct, not interchangeable
- Regulatory T-Cell Induction
- Upregulates FoxP3+ Tregs by 40–60% in chronic inflammation models
- No measurable effect on Treg populations
- Minimal Treg effect; primarily enhances NK/CTL cytotoxicity
- Tα1 is the only option for autoimmune or sepsis contexts requiring immune dampening
- Dendritic Cell Activation
- Increases CD86 expression 340%, IL-12 secretion 280% within 48 hours
- No dendritic cell effects documented
- Modest dendritic cell maturation but pro-inflammatory skew
- Tα1 produces the strongest antigen-presentation enhancement without systemic inflammation
- Clinical Evidence in Sepsis
- 22% relative risk reduction in 28-day mortality across 17 RCTs (n=2,082)
- No sepsis trials; mechanism not applicable
- Historically used but abandoned due to adverse effects
- Tα1 is the only peptide with replicated sepsis survival benefit in meta-analyses
- Dosing Window
- 1.6mg SC twice weekly (empirically derived therapeutic window)
- 5–10mg SC daily for tissue repair protocols
- 3–10 MIU SC three times weekly (highly variable)
- Tα1 dosing is the most standardised across indications
- Administration Route
- Subcutaneous injection (bioavailability ~65%)
- Subcutaneous or oral (oral bioavailability ~20%)
- Subcutaneous or intramuscular only
- Tα1 and IFN-α require injection; Tβ4 offers oral option but with reduced efficacy